Moreover, we compared the above analysis with the analysis at the target level, and results showed that increased levels of KRAS and CD44 in CRC were associated with upregulation of MAP3K10, TRIM71, and G3BP1 gene mutations, which promote proliferation, metastasis, and drug resistance [66,67,68]. This evidence concerns the gene G3BP1 and colorectal carcinoma.